Medivir AB Release: Positive Results From a Phase I Study With MIV-711 for the Treatment of Osteoarthritis and Other Bone Related Disorders
Published: Oct 09, 2013
Stockholm, Sweden – Medivir AB (OMX:MVIR) announced further results from the phase I clinical study on the investigational cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and other bone related disorders. The 7 day data was presented on October 6th at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting in Baltimore, USA.
Help employers find you! Check out all the jobs and post your resume.